Gamma Technologies acquires ProFEMAG portfolio
The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based in the US State of Illinois is now planning to establish a Global Center of Excellence for electrical machines in Basel.
Gamma Technologies (GT) is acquiring the FEMAG software portfolio. FEMAG is an electromagnetic simulation solution for electrical machines based on the physical finite element method. It has been continually further developed and enhanced by ProFEMAG AG and Semafor Informatik und Energie AG, which are both based in Basel. The project was first launched at the Institute of Electrical Machines at the Swiss Federal Institute of Technology in Zurich (ETH) in 1982.
FEMAG technologies have been integrated in the GT-SUITE system simulation platform from Gamma Technologies. They facilitate “a complete design solution for batteries, electric drives and power electronics”, explains Dimple Shah, GT President and CEO, in a press release issued by his company.
Global Center of Excellence in Basel
“The tight integration of our solutions into the GT-SUITE system simulation platform has opened new possibilities for the engineering community”, comments Walter Egli, CEO of ProFEMAG, in the press release, before adding that GT’s culture of innovation “provides an excellent home for FEMAG technologies and people”. According to Dr. Ronald Tanner, CTO of Semafor, this “next chapter with GT” will enable the company “to accelerate the pace of development”.
For future cooperation with ProFEMAG and Semafor, GT plans to set up a Global Center of Excellence in Basel. This will be an innovation hub for the research, development and deployment of multiphysics simulation technologies for the next generation of high-efficiency electric machine applications. The investment and innovation promotion agency Basel Area Business & Innovation will be supporting this project.
Share this article
You may also be interested in
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...Read More